Trial
NCT03988023
Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Ampio Pharmaceuticals. Inc.
Collaborators
—
Condition
Severe Osteoarthritis of the Knee
Intervention
Ampion
Why stopped
The AP-013 study was prematurely terminated by the sponsor after Data Safety Monitoring Board (DSMB) guidance.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-05